Clinical and investigational use of proteasome inhibitors for transplant rejection
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Clinical and investigational use of proteasome inhibitors for transplant rejection
Authors
Keywords
-
Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 20, Issue 11, Pages 1535-1542
Publisher
Informa Healthcare
Online
2011-09-16
DOI
10.1517/13543784.2011.618494
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Second Generation Proteasome Inhibitors: Carfilzomib and Immunoproteasome-Specific Inhibitors (IPSIs)
- (2011) D. J. Kuhn et al. CURRENT CANCER DRUG TARGETS
- Marizomib, a Proteasome Inhibitor for All Seasons: Preclinical Profile and a Framework for Clinical Trials
- (2011) B. C. Potts et al. CURRENT CANCER DRUG TARGETS
- Proteasome Inhibition with Bortezomib Depletes Plasma Cells and Autoantibodies in Experimental Autoimmune Myasthenia Gravis
- (2011) A. M. Gomez et al. JOURNAL OF IMMUNOLOGY
- Early and Late Acute Antibody-Mediated Rejection Differ Immunologically and in Response to Proteasome Inhibition
- (2011) R. Carlin Walsh et al. TRANSPLANTATION
- The Impact of Proteasome Inhibition on Alloantibody-Producing Plasma Cells In Vivo
- (2011) Tayyab S. Diwan et al. TRANSPLANTATION
- Bortezomib as the Sole Post-Renal Transplantation Desensitization Agent Does Not Decrease Donor-Specific Anti-HLA Antibodies
- (2010) R. Sberro-Soussan et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Immunoproteasome beta subunit 10 is increased in chronic antibody-mediated rejection
- (2010) Joanna Ashton-Chess et al. KIDNEY INTERNATIONAL
- Effect of the Proteasome Inhibitor Bortezomib on Humoral Immunity in Two Presensitized Renal Transplant Candidates
- (2010) Markus Wahrmann et al. TRANSPLANTATION
- Proteasome Inhibitor-Based Primary Therapy for Antibody-Mediated Renal Allograft Rejection
- (2010) R Carlin Walsh et al. TRANSPLANTATION
- The Role of Proteasome Inhibition With Bortezomib in the Treatment of Antibody-Mediated Rejection After Kidney-Only or Kidney-Combined Organ Transplantation
- (2010) Stuart M. Flechner et al. TRANSPLANTATION
- Reducing De Novo Donor-Specific Antibody Levels during Acute Rejection Diminishes Renal Allograft Loss
- (2009) M. J. Everly et al. AMERICAN JOURNAL OF TRANSPLANTATION
- The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition
- (2009) G. Bianchi et al. BLOOD
- Proteasome inhibition for antibody-mediated rejection
- (2009) Jason J Everly et al. Current Opinion in Organ Transplantation
- HLA-Specific Antibodies Developed in the First Year Posttransplant are Predictive of Chronic Rejection and Renal Graft Loss
- (2009) Po-Chang Lee et al. TRANSPLANTATION
- Proteasome Inhibition Causes Apoptosis of Normal Human Plasma Cells Preventing Alloantibody Production
- (2008) D. K. Perry et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Dampening Ab responses using proteasome inhibitors followingin vivo B cell activation
- (2008) Paolo Cascio et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis
- (2008) Kirsten Neubert et al. NATURE MEDICINE
- Bortezomib Provides Effective Therapy for Antibody- and Cell-Mediated Acute Rejection
- (2008) Matthew J. Everly et al. TRANSPLANTATION
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started